M. Almekinders

Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis.

Ron Wolterbeek, R. Wolterbeek, K. Cransberg, 2017, Clinical journal of the American Society of Nephrology : CJASN.

Learning to distinguish progressive and non-progressive ductal carcinoma in situ

N. Navin, S. Nik-Zainal, H. Davies, 2022, Nature Reviews Cancer.

Steric Hindrance and Fast Dissociation Explain the Lack of Immunogenicity of the Minor Histocompatibility HA-1Arg Null Allele 1

J. Drijfhout, S. Gras, M. Kester, 2009, The Journal of Immunology.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study

M. Schmidt, E. Rutgers, J. Wesseling, 2018, Clinical Cancer Research.

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ

C. Desmedt, A. Broeks, L. Wessels, 2021, npj Breast Cancer.

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ

C. Desmedt, A. Broeks, W. Zwart, 2021, NPJ breast cancer.

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk

Fei Yang, A. Broeks, I. Wistuba, 2022, British Journal of Cancer.

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study

P. V. van Diest, P. Westenend, C. Quinn, 2020, Breast Cancer Research and Treatment.

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS

A. Broeks, M. Schmidt, E. Rutgers, 2019, The American journal of surgical pathology.

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

P. Kristel, S. Nik-Zainal, H. Davies, 2023, Cancer cell.